Where metastatic prostate cancer treatment is heading
Metastatic prostate cancer · Updated Nov 15, 2026
Prostate cancer that has spread is treated first with hormone therapy: testosterone suppression (ADT) plus a stronger hormone pill such as abiraterone, enzalutamide, apalutamide or darolutamide, sometimes with docetaxel chemotherapy. Men now live years longer than a decade ago. When the cancer stops responding to hormones (castration-resistant), options include PARP inhibitors for DNA-repair gene changes, Lu-PSMA-617 radioligand therapy, radium-223, and chemotherapy. Research is moving these treatments earlier and testing new hormone-pathway drugs and immune approaches.
- 700studies open or running
- 98phase 3 trials
- 1,358papers published this year
- 40NIH-funded projects
-
Now
Nov 2026
PARP inhibitors move earlierHappened 45.8 months median survival
Niraparib delayed progression in hormone-sensitive disease with DNA-repair changes; talazoparib plus enzalutamide extended survival to 45.8 vs 37.0 months.
45.8: months median survival, vs 37.0 with enzalutamide alone.
Radioligands move earlierHappened 28% lower risk of progression
Lu-PSMA-617 added to first hormone therapy cut the risk of progression by 28%; radium-223 plus enzalutamide extended survival.
28%: lower risk of progression or death with Lu-PSMA-617 added.
Long-term hormone therapy resultsHappened 50% alive at 8 years
In ENZAMET, 50% of men on enzalutamide were alive at 8 years vs 40%.
50%: alive at 8 years, vs 40% with the older drug.
-
6 months
by May 2027
Talazoparib in hormone-sensitive diseaseLikely 45.8 months median survival (later stage)
Pfizer's TALAPRO-3 (599 men with DNA-repair changes) finished its main follow-up in February 2026; results are expected.
45.8: months median survival in castration-resistant disease, vs 37.0.
An EZH2 inhibitor with enzalutamidePossible
Pfizer's MEVPRO-1 (609 men) compares mevrometostat plus enzalutamide with chemotherapy or another hormone drug after abiraterone; due February 2027.
Capivasertib with docetaxelPossible 33.2 months without progression (earlier stage)
AstraZeneca's CAPItello-280 (1,035 men) tests capivasertib with chemotherapy in castration-resistant disease; its main follow-up ended March 2026.
33.2: months without progression in PTEN-deficient disease, vs 25.7.
-
12 months
by Nov 2027
A next-generation PARP inhibitorPossible
AstraZeneca's EvoPAR-PR01 (1,898 men) adds saruparib to hormone therapy at diagnosis, for men with or without DNA-repair changes; due September 2027.
Androgen receptor degradersPossible
Bristol Myers Squibb's rechARge (960 men) tests BMS-986365, which breaks down the androgen receptor, against a switch of hormone drug or docetaxel; due September 2027.
-
3 years
by late 2029
Blocking hormone production at the sourcePossible
Merck's OMAHA trials (about 2,600 men) test opevesostat, which shuts down the first step in making all steroid hormones; due 2028.
Antibody-drug conjugates and T-cell engagersPossible 42.4% PSA fell by half (early trial)
Merck's ifinatamab deruxtecan trial (due June 2028) and J&J's pasritamig trial (due August 2028) target B7-H3 and KLK2.
42.4%: had PSA fall by at least half in an early trial.
-
5 years
by late 2031
Smarter sequencing of treatmentsPossible
TRIPLE-SWITCH (due March 2031) tests docetaxel before switching hormone drugs; saruparib is tested after earlier hormone therapy (due May 2031).
Lu-PSMA as part of first treatmentLong shot 28% lower risk of progression
If PSMAddition shows a survival benefit, radioligand therapy could join hormone therapy at diagnosis for PSMA-positive disease.
28%: lower risk of progression or death with Lu-PSMA-617 added.
The research paths
PARP inhibitors and gene testing
45.8 months median survivalDetails and 3 trialsHide
PARP inhibitors work best when DNA-repair genes such as BRCA2 are altered. Trials are moving them to diagnosis and testing more selective drugs.
WatchTALAPRO-3; EvoPAR-PR01.
- Talazoparib plus enzalutamide, hormone-sensitive (TALAPRO-3)Pfizer · 599 people · fully enrolled Feb 2026
- Saruparib, hormone-sensitive (EvoPAR-PR01)AstraZeneca · 1,898 people · fully enrolled Sep 2027
- Saruparib after earlier hormone therapy (EvoPAR-PR05)AstraZeneca · 1,330 people · enrolling May 2031
Radioligand therapy
28% lower risk of progressionDetailsHide
Radioactive drugs that seek out PSMA or bone. Lu-PSMA-617 is moving from late to first treatment.
WatchPSMAddition survival data.
New hormone-pathway drugs
33.2 months without progressionDetails and 7 trialsHide
Drugs that block hormone production at its source, break down the androgen receptor, or block EZH2 or AKT to overcome resistance.
WatchMEVPRO-1; rechARge; OMAHA.
- Mevrometostat plus enzalutamide (MEVPRO-1)Pfizer · 609 people · fully enrolled Feb 2027
- Mevrometostat plus enzalutamide (MEVPRO-2)Pfizer · 900 people · enrolling Sep 2027
- Mevrometostat, hormone-sensitive (MEVPRO-3)Pfizer · 1,000 people · enrolling Sep 2028
- BMS-986365, an androgen receptor degrader (rechARge)Bristol Myers Squibb · 960 people · fully enrolled Sep 2027
- Opevesostat vs switch of hormone drug (OMAHA-003)Merck · 1,310 people · enrolling Nov 2028
- Opevesostat, earlier castration-resistant disease (OMAHA-004)Merck · 1,314 people · enrolling May 2028
- Capivasertib plus docetaxel (CAPItello-280)AstraZeneca · 1,035 people · fully enrolled Mar 2026
Immune and antibody approaches
42.4% PSA fell by halfDetails and 2 trialsHide
T-cell engagers aimed at KLK2 or STEAP1, and antibody-drug conjugates aimed at B7-H3.
WatchKLK2-comPAS; I-DXd trial.
Using chemotherapy better
Details and 1 trialsHide
Trials testing when docetaxel helps most alongside modern hormone pills.
WatchTRIPLE-SWITCH.
Borrowed from other cancers
From Breast cancer
Capivasertib
Phase 3
An AKT inhibitor approved for HR-positive breast cancer with PI3K pathway changes.
From Small cell lung cancer
Ifinatamab deruxtecan (I-DXd)
Phase 3
A B7-H3 antibody-drug conjugate first developed in small cell lung cancer.
From Ovarian and breast cancer
Niraparib and talazoparib
Approved
PARP inhibitors first approved for BRCA-related ovarian and breast cancers.
Open to join now
-
Hormone-sensitive disease
Mevrometostat plus enzalutamide
Locations and eligibility → -
Hormone-sensitive disease after earlier hormone therapy
Saruparib with hormone therapy
Locations and eligibility → -
Castration-resistant, after one hormone pill
Opevesostat
Locations and eligibility → -
Castration-resistant disease
Ifinatamab deruxtecan
Locations and eligibility → -
Late-line castration-resistant disease
Pasritamig
Locations and eligibility →
See every recruiting Metastatic prostate cancer trial →
When the trials finish
Completion dates the trials registered. Results usually follow 3 to 12 months later.
- Heating up
- Maturing
- Early
- Cooling
- Fully enrolled, waiting on results
- Still enrolling
What just happened
Lu-PSMA-617 added to first hormone therapy delays progression
PSMAddition, The Lancet.
Enzalutamide benefit holds at 8 years
ENZAMET, Annals of Oncology.
Niraparib plus abiraterone delays progression with DNA-repair changes
AMPLITUDE, Nature Medicine.
Standard treatment today
- Newly diagnosed, hormone-sensitiveADT plus abiraterone, enzalutamide, apalutamide or darolutamide; docetaxel added for high-volume disease; radiation to the prostate for low-volume disease.
- Castration-resistant, first treatmentA different hormone pill, a PARP inhibitor combination if DNA-repair genes are altered, or docetaxel.
- After hormone pills and chemotherapyLu-PSMA-617 if PSMA-positive on PET, cabazitaxel, radium-223 for bone metastases.
- Testing to ask aboutGermline and tumor genetic testing (BRCA and other HRR genes), and PSMA PET.
How to read this page, and sourcesHow to read this page, and sources
- Results differ by whether cancer is hormone-sensitive or castration-resistant, by volume of metastases and by genetic changes; ask which group you are in.
- Forecasts are editorial judgments by Find a Trial, not predictions from sponsors or regulators.
See Metastatic prostate cancer trials recruiting now →